一种新型人白细胞介素-23A过表达系统性红斑狼疮小鼠模型
研究通过显微注射人IL23A基因片段构建过表达人IL-23A的转基因小鼠(TghIL-23A),该小鼠出现蛋白尿、抗双链DNA抗体、皮肤严重炎症病变及肾脏和肺部较轻表型,经古塞奇尤单抗治疗后这些病理特征被逆转。
要点
- TghIL-23A小鼠出现蛋白尿、抗dsDNA抗体及皮肤、肾脏、肺部炎症病变。
- TghIL-23A病理特征与人SLE患者观察到的特征高度相似。
- 古塞奇尤单抗治疗可逆转TghIL-23A小鼠的病理特征。
核心结论
- 研究成功生成并表征了一种新型SLE遗传小鼠模型,为人IL-23A的病因致病作用提供了概念验证。
- 该模型寿命正常,整合了人类疾病复杂性和慢性化的若干特征,是研究IL-23依赖致病机制及评估抗人IL-23A或模拟疾病相关治疗疗效的有吸引力的临床前工具。
研究设计与样本
- 通过显微注射人IL23A基因片段(两侧为人IL23A基因5'调控序列和人β-珠蛋白3'非翻译区)至CBA×C57BL/6受精卵,生成TghIL-23A转基因小鼠。
- 通过血液学和生化分析、细胞因子和抗核抗体检测以及皮肤和肾脏组织病理学检查评估TghIL-23A病理。
- 在每组八只混合性别小鼠中评估抗人IL-23A治疗药物古塞奇尤单抗的反应,皮下给药每周两次持续10周,采用临床、生物标志物和组织病理学读数。
主要发现
- TghIL-23A小鼠表现出人IL-23A与小鼠IL-23/IL-12p40之间的相互作用,并发展为以蛋白尿、抗双链DNA抗体、皮肤严重炎症病变以及肾脏和肺部较轻表型为特征的慢性多器官自身免疫病。
- TghIL-23A病理特征与人SLE患者观察到的特征高度相似。
- TghIL-23A病理特征在古塞奇尤单抗治疗后被逆转。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Interleukin-23 (IL-23) is a crucial cytokine implicated in chronic inflammation and autoimmunity, associated with various diseases such as psoriasis, psoriatic arthritis, and systemic lupus erythematosus (SLE). This study aimed to create and characterize a transgenic mouse model overexpressing human IL-23A (TghIL-23A), providing a valuable tool for investigating the pathogenic role of human IL-23A and evaluating the efficacy of anti-human IL-23A therapeutics. METHODS: TghIL-23A mice were generated via microinjection of CBA × C57BL/6 zygotes with a fragment of the human IL23A gene, flanked by its 5'-regulatory sequences and the 3' untranslated region of human β-globin. The TghIL-23A pathology was assessed through hematologic and biochemic analyses, cytokine and antinuclear antibody detection, and histopathologic examination of skin and renal tissues. The response to the anti-human IL-23A therapeutic agent guselkumab was evaluated in groups of eight mixed-sex mice receiving subcutaneous treatment twice weekly for 10 weeks using clinical, biomarker, and histopathologic readouts. RESULTS: TghIL-23A mice exhibited interactions between human IL-23A and mouse IL-23/IL-12p40 and developed a chronic multiorgan autoimmune disease marked by proteinuria, anti-double-stranded DNA antibodies, severe inflammatory lesions in the skin, and milder phenotypes in the kidneys and lungs. The TghIL-23A pathologic features exhibited significant similarities to those observed in human patients with SLE, and they were reversed following guselkumab treatment. CONCLUSION: We have generated and characterized a novel genetic mouse model of SLE, providing proof-of-concept for the etiopathogenic role of human IL-23A. This new model has a normal life span and integrates several characteristics of the human disease's complexity and chronicity, making it an attractive preclinical tool for studying IL-23-dependent pathogenic mechanisms and assessing the efficacy of anti-human IL-23A or modeled disease-related therapeutics.
引用
- Christodoulou-Vafeiadou E, Geka C, Iliopoulou L, et al. A Novel Human Interleukin-23A Overexpressing Mouse Model of Systemic Lupus Erythematosus. Arthritis Rheumatol. 2024. PMID: 38361183. doi:10.1002/art.42830
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。